Both trials aim to evaluate efficacy (change from baseline to week 24 in glycated hemoglobin level, daily bolus insulin, fasting plasma glucose, body weight) and safety (number of severe hypoglycemia [1] and diabetic ketoacidosis [DKA] episodes) of the use of sotagliflozin, 200 mg or 400 mg, in adult patients with type 1 diabetes. This evidence concerns the gene INS and type 1 diabetes mellitus.